The benefits of mucosal vaccines over injected vaccines are difficult to ascertain since mucosally 3 1 administered vaccines often induce serum antibody responses of lower magnitude than those induced by 3 2 injected vaccines. This study aimed to determine if mucosal vaccination using a modified vaccinia Ankara 3 3 expressing HIV-1 gp120 (MVA-g120) prime and HIV-1 gp120 protein boost could be optimized to induce serum 3 4 antibody responses similar to those induced by an intramuscularly (IM) administered MVA prime/gp120 boost 3 5 to allow comparison of an IM immunization regimen to a mucosal vaccination regimen for their ability to protect 3 6 against a low dose rectal SHIV challenge while inducing similar serum anti-HIV-1 antibody responses. A 3-fold 3 7
rhesus macaque animal models`). Our work highlights the ability of rabbits to serve as a valuable small animal 2 9 model system for the development of mucosal HIV vaccination strategies although more studies are needed to 3 0 better define vaccination regimens that enhance the induction of antigen-specific mucosal IgA responses.
1
We chose to model our prime/boost regimen off the canarypox prime/ gp120 boost used in the RV144 3 2 clinical trial as that prime/boost regimen showed moderate protection from challenge (2). A vaccine regimen 3 3 that is partially protective should be the most sensitive to any beneficial effects from mucosal vaccines. 3 4
Unfortunately, no protection from challenge was observed in either vaccine group tested in the present study. 3 5
Several factors likely played a role in the lack of protection observed. First, others have seen a lack of 3 6 protection against the same SHIV strain utilized in our study even after several additional boosters of gp120 3 7 (51). However, protection was observed when a pentavalent gp120 vaccine was used, and the protective 3 8 efficacy was correlated to non-neutralizing antibody responses (82) . ADCC responses were induced by our 3 9 prime/boost regimens in rabbits and NHPs, but both the lack of protective efficacy and the ADCC responses The decision to use Addavax, an oil-in-water emulsion, as the adjuvant in our IM administered vaccines 4 3 instead of alum, which was used in the RV144 trials, may have resulted in lower vaccine efficacy. Vaccari et 4 4 al., reported that a prime/boost vaccination regimen consisting of priming with the canarypox vector ALVAC 4 5 and boosting with an adjuvanted gp120 vaccines was effective at preventing SIV acquisition only when the 4 6 boosting vaccines contained alum (62). The lack of efficacy of booster vaccines adjuvanted with MF-59, 4 7 another oil-in-water adjuvant, was correlated to mucosal innate lymphoid cells, mucosal V2 antibodies, and 4 8 RAS activation. Additional studies are needed to determine if mucosal vaccination can overcome any skewing 4 9 induced by the use of oil-in-water adjuvants for systemic vaccines. 5 0
In conclusion, optimized nasal HIV vaccination regimens are capable of inducing high titer, functional 5 1 serum antibody responses similar to IM vaccination regimens. More work is needed to optimize mucosal 5 2 immunization for the induction of durable, elevated anti-HIV-1 IgA in mucosal secretions and to determine if 5 3 mucosal anti-HIV IgA influences protection against mucosal SHIV challenge. 5 4 PFU MVAdelta5gp120 200 50; 30" rest Rest: seconds the animal is rested after an aliquot of the vaccine was delivered to a specific nostril prior to receiving another aliquot of the vaccine. The animal 0 was maintained in dorsal recumbency with isoflurane administered as needed to maintain surgical anesthesia for the indicated number of seconds prior to 1 receiving another aliquot of vaccine to that nostril or being placed in sternal recumbency for recovery 2 3 4 5 6 7 8 9 0 1 2 3 4 5 6 7 8 6 9 Responders 0/5 4/5 1/5 1/5 0/5 GMT 1:8 +/-1 1:74 +/-7* 1:9 +/-1 1:18 +/-6 1:8 +/-1 GMT-geometric mean titer +/-geometric standard deviation factor shown *significantly different from mice receiving unadjuvanted gp120 I  n  t  r  a  n  a  s  a  l  v  a  c  c  i  n  e  s  a  d  j  u  v  a  n  t  e  d  w  i  t  h  t  h  e  m  a  s  t  c  e  l  l  a  c  t  i  v  a  t  i  n  g  a  d  j  u  v  a  n  t  s  c  o  m  p  o  u  n  d  4  8  /  8  0  o  r  2  0  M  a  s  t  o  p  a  r  a  n  7  i  n  d  u  c  e  s  t  r  o  n  g  e  r  s  e  r  u  m  g  p  1  2  0  -I  g  G  t  i  t  e  r  s  t  h  a  n  i  n  d  u  c  e  d  b  y  c  h  o  l  e  r  a  t  o  x  i  n  o  r  m  o  n  o  p  h  o  s  p  h  o  l  i  p  i  d  A   .   2  1   C  5  7  B  L  /  6  m  i  c  e  (  n  =  5  /  g  r  o  u  p  )  w  e  r  e  v  a  c  c  i  n  a  t  e  d  o  n  d  a  y  0  ,  7  &  2  1  w  i  t  h  1  0  µ  g  g  p  1  2  0  a  n  d  e  i  t  h  e  r  n  o  a  d  j  u  v  a  n  t  ,  5  n  M   2  2   M  7  ,  1  5  µ  g  c  4  8  /  8  0  ,  1  µ  g  C  T  ,  o  r  1  0  µ  g  M  P  L  .  S  e  r  u  m  w  a  s  c  o  l  l  e  c  t  e  d  o  n  d  a  y  3  5  a  n  d  g  p  1  2  0  -s  p  e  c  i  f  i  c  I  g  G  t  i  t  e  r  s   2  3   d  e  t  e  r  m  i  n  e  d  b  y  E  L  I  S  A  .  M  i  c  e  r  e  c  e  i  v  i  n  g  v  a  c  c  i  n  e  s  a  d  j  u  v  a  n  t  e  d  w  i  t  h  c  4  8  /  8  0  o  r  M  7  h  a  d  s  i  g  n  i  f  i  c  a  n  t  l  y  h  i  g  h  e  r  s  e  r  u 
We would like to thank the animal husbandry staff, veterinary technicians, veterinarians, and diagnostic lab 2 4 personnel at Duke's Division of Lab Animal Resources for the care they provided our animals and for 2 5 assistance with animal procedures. We would also like to recognize Moses Wanyonyi and Michael Peace for 2 6 assistance with rabbit procedures and Carolyn Weinbaum for help obtaining the primates.
7
For assay and reagent support we would like to thank: K  i  r  w  a  n  S  M  ,  A  b  r  a  h  a  m  S  N  ,  S  t  a  a  t  s  H  F  ,  H  i  c  k  e  y  A  J  .  2  0  1  2  .  S  t  a  b  l  e  d  r  y  p  o  w  d  e  r  f  o  r  m  u  l  a  t  i  o  n  f  o  r  n  a  s  a  l  d  e  l  i  v  e  r  y  0  4  o  f  a  n  t  h  r  a  x  v  a  c  c  i  n  e  .  J  P  h  a  r  m  S  c  i  1  0  1  :  3  1  -4  7  .  0  5  5  3  .  P  o  l  l  a  r  a  J  ,  H  a  r  t  L  ,  B  r  e  w  e  r  F  ,  P  i  c  k  e  r  a  l  J  ,  P  a  c  k  a  r  d  B  Z  ,  H  o  x  i  e  J  A  ,  K  o  m  o  r  i  y  a  A  ,  O  c  h  s  e  n  b  a  u  e  r  C  ,  K  a  p  p  e  s  J  C  ,  R  o  e  d  e  r  e  r  M  ,  0  6  H  u  a  n  g  Y  ,  W  e  i  n  h  o  l  d  K  J  ,  T  o  m  a  r  a  s  G  D  ,  H  a  y  n  e  s  B  F  ,  M  o  n  t  e  f  i  o  r  i  D  C  ,  F  e  r  r  a  r  i  G  .  2  0  1  1  .  H  i  g  h  -t  h  r  o  u  g  h  p  u  tu  a  n  t  i  t  a  t  i  v  e  0  7  a  n  a  l  y  s  i  s  o  f  H  I  V  -1  a  n  d  S  I  V  -s  p  e  c  i  f  i  c  A  D  C  C  -m  e  d  i  a  t 
